More tools:Markets·Screener·Research·Chat

Entera Bio Ltd. Ordinary Shares (ENTX) Financial Statements

Entera Bio Ltd. Ordinary Shares
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001T8ZSW3
XNAS · usd
3.01▲ 0.01 (0.33%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close3.00
Day's Range2.82 – 3.07
52-Week Range0.91 – 4.20
Volume824.6K
Avg Volume674.2K
Share Statistics
Shares Outstanding
Employees22
ExchangeXNAS
Listed2018-06-28
Share count as of August 3, 2026
Loading Income Statement…
Key questions about Entera Bio Ltd. Ordinary Shares (ENTX)
What is Entera Bio Ltd. Ordinary Shares's Market Cap?
Entera Bio Ltd. Ordinary Shares's Market Cap is $521.2M, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's Enterprise Value?
Entera Bio Ltd. Ordinary Shares's Enterprise Value is $509.8M, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's EV / EBITDA?
Entera Bio Ltd. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's Revenue (TTM)?
Entera Bio Ltd. Ordinary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's Net Income (TTM)?
Entera Bio Ltd. Ordinary Shares's Net Income (TTM) is -$17.0M, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's EBITDA?
Entera Bio Ltd. Ordinary Shares's EBITDA is -$14.4M, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's Diluted EPS (TTM)?
Entera Bio Ltd. Ordinary Shares's Diluted EPS (TTM) is -0.10, based on as-reported figures from SEC (XBRL) filings.
What is Entera Bio Ltd. Ordinary Shares's Net Debt?
Entera Bio Ltd. Ordinary Shares's Net Debt is -$11.3M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
REVENUES
YoY growth—-100.0%-100.0%-100.0%
COST OF REVENUES
GROSS PROFIT
% of revenue————
OPERATING EXPENSES:
Research and development, net
General and administrative
Other income————
TOTAL OPERATING EXPENSES
% of revenue————
OPERATING LOSS
% of revenue————
FINANCIAL EXPENSES (INCOME), NET
Segment net loss
% of revenue————
LOSS PER SHARE BASIC
LOSS PER SHARE DILUTED